Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 14/20 | 0.65 |
| ▸ | ADORA2A | P29274 | 12/20 | 0.65 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | PIP4K2A | P48426 | 1/20 | 0.49 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9791332 | 0.90 | ADORA1 (0.62) | ADORA1ADORA2AADORA2BKMT2AKDM4E | |
| SCHEMBL27914182 | 0.83 | ADORA2A (0.68) | ADORA1ADORA2AMEN1KMT2ASCN9A | |
| SCHEMBL6072767 | 0.80 | ADORA2A (0.60) | ADORA1ADORA2AADORA2BKMT2APIP4K2A | |
| SCHEMBL6072090 | 0.77 | ADORA2A (0.56) | ADORA1ADORA2AMEN1KMT2AKDM4E | |
| SCHEMBL6252164 | 0.75 | KDM4E (0.60) | ADORA1ADORA2AKMT2AKDM4EALDH1A1 | |
| SCHEMBL6072331 | 0.74 | BCHE (0.53) | ADORA1ADORA2AMEN1KMT2AKDM4E | |
| SCHEMBL6072047 | 0.74 | ACP1 (0.45) | ADORA1ADORA2AMEN1KMT2APIP4K2A | |
| SCHEMBL6072030 | 0.73 | ADORA2A (0.46) | ADORA1ADORA2AKMT2APIP4K2AKDM4E | |
| SCHEMBL28232225 | 0.73 | ADORA2A (0.67) | ADORA2AKMT2ASCN9AALDH1A1 | |
| SCHEMBL6826836 | 0.72 | DHODH (0.73) | ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060264460-A1 | 3-Cyanoquinoline inhibitors of Tpl2 kinase and methods of making and using the same | WYETH (US) | 2006-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264460-A1 | 3-Cyanoquinoline inhibitors of Tpl2 kinase and methods of making and using the same | TNNI3K, CSNK1A1L, CDKL1 | ADORA1 2355/4885ADORA2A 2729/4885ADORA2B 3405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.